Belimumab

Introduction Overview

Generic Name

belimumab

Brand Name

Benlysta

Dosage Form

single-dose vial for intravenous infusion (120 mg/vial, 400 mg/vial), prefilled syringe for subcutaneous use (200 mg/mL), prefilled autoinjector for subcutaneous use (200 mg/mL)

Drug Class

Selective immunosuppressants, B-lymphocyte stimulator (BLyS)-specific inhibitors

Pharmacokinetics

Absorption

Belimumab is administered intravenously or subcutaneously, bypassing the gastrointestinal tract; therefore, systemic absorption is rapid and near-complete following IV infusion, with bioavailability approaching 100%. Subcutaneous administration results in approximately 74% bioavailability, with peak serum concentrations attained after about 3 to 4 days post-injection. Factors influencing absorption include injection site blood flow and lymphatic system activity. Absorption is generally consistent across populations but may vary with obesity or edema.

Distribution

Belimumab circulates in the plasma primarily as an intact monoclonal antibody with a volume of distribution approximating plasma volume (around 5 to 7 liters), indicating limited distribution beyond extracellular fluid compartments. It does not readily cross cell membranes or the blood-brain barrier. Binding to soluble BLyS reduces free circulating BLyS levels, contributing to its pharmacodynamics. Distribution kinetics are typical of IgG1 monoclonal antibodies, with relatively slow extravascular distribution.

Metabolism

As a monoclonal antibody, belimumab is metabolized via proteolytic catabolism into small peptides and amino acids within the reticuloendothelial system, similar to endogenous IgG molecules. It is not metabolized via cytochrome P450 enzymes; thus, it has low potential for hepatic drug-drug interactions. The metabolic clearance pathways are non-saturable under therapeutic concentrations, following typical antibody degradation processes.

Elimination

Belimumab is eliminated primarily through proteolytic catabolism, with a terminal half-life averaging approximately 19 days (range 8 to 22 days). Clearance is slow and mediated via reticuloendothelial cells and target-mediated disposition upon binding to BLyS. Renal and hepatic impairments do not significantly affect elimination due to the non-renal route of clearance. The extended half-life supports dosing intervals of weekly to monthly administration.

Dosage Forms

Adults

Benlysta is available as either intravenous infusions or subcutaneous injections for adults. IV doses are 10 mg/kg given every 2 weeks for the first 3 doses, then every 4 weeks thereafter. Subcutaneous dosing is 200 mg once weekly for active SLE, or 400 mg once weekly for initial 4 doses followed by 200 mg weekly for lupus nephritis.

Adolescents

Children aged 5 years and older can receive Benlysta by either IV or SC routes. IV dosing follows the same 10 mg/kg regimen as adults. For SC administration, dosing varies by weight: those ≥40 kg receive 200 mg weekly for SLE; 400 mg weekly for 4 doses then 200 mg weekly for lupus nephritis. Those 15–40 kg receive 200 mg every 2 weeks or weekly, depending on indication.

Special Populations

Benlysta use in pediatrics under 5 years has not been established. No dosage adjustments are necessary for mild to moderate renal or hepatic impairment given metabolic elimination. Caution advised in patients with active infections or immunosuppression. Dosing in elderly is not specifically adjusted but requires monitoring. The autoinjector is approved for patients aged 5 and older weighing at least 15 kg. Recommended storage is refrigerated, with room temperature exposure for up to 12 hours prior to injection.

Mechanism Of Action

Belimumab is a human monoclonal IgG1λ antibody specifically targeting the B-lymphocyte stimulator protein (BLyS), also known as B-cell activating factor (BAFF). BLyS is a tumor necrosis factor (TNF) family ligand critical for B-cell survival, differentiation, and maturation. By binding soluble BLyS, belimumab prevents BLyS interaction with its receptors on B cells (such as BAFF-R), thereby inhibiting the BLyS-mediated survival signal. This action selectively reduces the survival of autoreactive B cells that would otherwise produce pathogenic autoantibodies in systemic lupus erythematosus (SLE) and lupus nephritis. Cellular pathways affected include modulation of B-cell receptor (BCR) signaling and downstream NF-κB activation essential for B-cell homeostasis. Clinically, this results in diminished autoantibody production, decreased immune complex formation, and amelioration of inflammatory tissue damage. Belimumab's selective immunosuppressive profile contrasts with broad-spectrum immunosuppressants, offering targeted suppression of humoral autoimmunity with a potentially improved safety profile. Clinical studies have demonstrated reductions in disease activity indices and flare rates in treated patients, validating its mechanism. Comparative biologics, such as rituximab, deplete B cells nonspecifically, whereas belimumab specifically inhibits survival factors, enabling partial B-cell modulation.

Pharmacological Actions

Selective inhibition of B-lymphocyte stimulator (BLyS), reducing B-cell survival
Decreases production of pathogenic autoantibodies in systemic lupus erythematosus and lupus nephritis
Modulates humoral immune response by lowering autoreactive B-cell populations
Reduces disease activity and frequency of flares in lupus patients
Spares other immune cells, providing targeted immunosuppression
Facilitates corticosteroid-sparing effects in lupus management
Improves symptoms like fatigue, joint and muscle pain by controlling inflammation
Maintains partial immune function to reduce risk of severe immunosuppression
Compatible with concomitant standard lupus therapies such as antimalarials and corticosteroids
Demonstrates delayed onset of maximal effect due to modulation of B-cell populations
Administered via intravenous infusion or subcutaneous injection formulations
Suitable for adults and pediatric patients aged 5 years and older at specific dosing
Minimal interference with cytochrome P450 enzymes and typical drug metabolism pathways
May reduce need for other immunosuppressive medications by improving disease control
Possesses a long half-life allowing intermittent dosing schedules

Therapeutic Clinical Uses

Treatment of active systemic lupus erythematosus (SLE) in adults and children aged 5 years and older
Management of active lupus nephritis in conjunction with standard therapy in adults and children aged 5 years and older
Reduction of disease activity and prevention of flares in SLE patients
Adjunctive treatment to decrease corticosteroid dose requirements in lupus management
Improvement of symptoms such as fatigue, joint, and muscle pain associated with SLE
Treatment for patients inadequately responsive to standard immunosuppressive therapy
Used in patients where broad immunosuppression presents high risk of adverse effects
Provides a targeted approach to modulate humoral autoimmunity in lupus
Alternative therapy for patients unable to tolerate other biologics or immunosuppressants
Management tool to potentially reduce long-term organ damage in lupus nephritis
Not approved for severe active central nervous system lupus due to lack of evaluation
Used as a maintenance therapy to sustain disease remission
Treatment option for pediatric lupus patients above age 5 with active disease
Part of combination therapy regimens in SLE clinical practice settings
Indicated for patients at risk of lupus-related complications due to uncontrolled disease

Side Or Adverse Effects

Nausea and gastrointestinal discomfort
Diarrhea
Fever (pyrexia)
Upper respiratory tract infections: sore throat, nasopharyngitis
Bronchitis and persistent cough
Injection site reactions: pain, itching, redness, swelling
Musculoskeletal pain such as pain in arms or legs
Headache including migraine
Neuropsychiatric symptoms: depression, insomnia
Hypersensitivity or allergic reactions including rash and itching
Serious infections potentially requiring hospitalization
Mental health concerns including suicidal ideation and mood disturbances
Rare occurrence of progressive multifocal leukoencephalopathy (PML)
Potential risk of malignancies due to immunosuppression
Fatigue is commonly improved but may also be an adverse effect in rare cases

Precautions

Evaluate for active infections prior to initiation; avoid if infection present
Monitor for infusion or injection-related hypersensitivity reactions
Screen mental health status before and during therapy due to risk of depression and suicidal thoughts
Avoid live vaccines during treatment due to immunosuppression
Use caution in patients with history of malignancies
Monitor closely for signs of serious infections including sepsis
Evaluate pregnant patients or those planning pregnancy carefully; counsel on contraception
Monitor pediatric patients especially for dosing accuracy and adverse effects
Use cautiously in patients on concomitant immunosuppressive or biologic therapies
Test for tuberculosis prior to therapy initiation where appropriate
Prepare to manage anaphylaxis or severe allergic reactions during infusion
Avoid administration in patients with known hypersensitivity to belimumab or excipients
Ensure proper storage and handling to maintain drug integrity
Educate patients on recognizing signs of infection and adverse effects
Regularly assess efficacy and consider alternative therapies if no clinical benefit observed

Warnings

Serious and potentially fatal infections can occur, including opportunistic infections
Hypersensitivity reactions including anaphylaxis can occur during or post-infusion
Risk of progressive multifocal leukoencephalopathy (PML) with immunosuppression
Mental health adverse events including new or worsening depression and suicidal ideation
Potential increased risk of malignancies due to immune modulation
Live vaccines are contraindicated during treatment and until immune recovery
Infusion reactions require immediate medical intervention and discontinuation if severe
Delayed hypersensitivity reactions can present days after administration
Not evaluated for severe active central nervous system lupus; efficacy unknown
Use in pregnancy only if potential benefits outweigh risks due to unknown fetal effects
Monitor for secondary autoimmune conditions emerging during therapy
Avoid abrupt discontinuation to prevent disease flare
Risk of infusion site reactions leading to tissue irritation or necrosis if improperly administered
Safety and efficacy in patients under 5 years old not established
Closely monitor patients with history of mental illness for behavioral changes

Contraindications

Known hypersensitivity to belimumab or any components of the formulation
Active severe infections contraindicate initiation of therapy
Concurrent administration of live vaccines
Patients with severe active central nervous system lupus due to lack of safety data
Use during pregnancy unless clearly necessary and benefit outweighs risk
Breastfeeding unless risk-benefit assessment by healthcare provider supports use
Patients with history of severe allergic reactions to monoclonal antibodies unless benefit justifies risk
Concomitant use with other biologic B-cell therapies like rituximab is discouraged due to infection risk
Known immunodeficiency syndromes not contraindicated but warrant caution
Patients unable to comply with monitoring or administration schedules
Severe hepatic impairment has not been studied and should generally be avoided
History of progressive multifocal leukoencephalopathy (PML)
Concurrent participation in other investigational drug studies involving immunomodulation
Known malignancy risks must be weighed carefully before use
Uncontrolled psychiatric disorders making adherence unlikely

Drug Interactions

Concurrent use with other biologic agents, such as rituximab, increases risk of serious infections and systemic reactions
Live vaccines are contraindicated during benlysta therapy; decreased vaccine efficacy
No significant interactions with cytochrome P450 metabolized drugs as belimumab is not CYP metabolized
Potential additive immunosuppressive effects when combined with corticosteroids or other immunosuppressants
No significant interaction with antimalarials commonly used in lupus
Herbal supplements and vitamins have no known significant interactions but should be disclosed
Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used concomitantly without known interaction
No impact on metabolism of oral contraceptives documented
Prolonged immunosuppression may alter response to infections when combined with chemotherapy
No clinical data on combination with biological TNF inhibitors; caution advised
No demonstrated pharmacokinetic interactions with commonly used antibiotics
Caution with concurrent cyclophosphamide use due to enhanced immunosuppression risk
Interaction potential with immunomodulators like azathioprine requires monitoring
No known interaction with medications for comorbid conditions such as hypertension or diabetes
Avoid abrupt discontinuation of concomitant medications without consulting healthcare provider

Preparations Of The Drug

Single-dose vial for intravenous infusion: 120 mg lyophilized powder requiring reconstitution
Single-dose vial for intravenous infusion: 400 mg lyophilized powder requiring reconstitution
Single-dose prefilled syringe for subcutaneous injection, 200 mg/mL, intended for adults aged 18 and older
Single-dose prefilled autoinjector for subcutaneous injection, 200 mg/mL, intended for adults and children five years and older weighing at least 15 kg
Lyophilized powder formulation for IV reconstitution supplied with diluents and infusion accessories
Commercial packaging includes vial kits and subcutaneous administration devices
Storage recommendations include refrigeration at 2°C to 8°C in original carton protected from light
Do not freeze or shake formulations to prevent protein denaturation
Prefilled syringe and autoinjector designed for single-use only and must be discarded after use
Multiple dosing options allow flexibility in clinical administration routes
No generic or biosimilar versions currently approved; brand product exclusive
Available in specifically designed patient-friendly devices to facilitate self-injection
Provided with detailed instructions for use to ensure proper subcutaneous administration
Packaging designed to maintain sterility and prevent contamination
Manufactured and distributed by GlaxoSmithKline LLC, Philadelphia, PA, USA